

Health Technology Assessment (HTA) Consumer Consultative Committee Communiqué

The HTA Consumer Consultative Committee (CCC) met on Wednesday, 27th March 2019 in Canberra. This was the first face-to-face meeting for 2019.

Attendees

Attendees included consumer representatives from the Pharmaceutical Advisory Committee (PBAC), the Prostheses Listing Advisory Committee (PLAC) and the Medical Services Advisory Committee (MSAC) and their subcommittees. A consumer representative from the Therapeutic Goods Administration (TGA) Advisory Committee on Medicines (ACM) was also in attendance along with representatives of the Department of Health. Members were given a presentation by the HTA Improvement Section in respect to the proposed new Medicine Status Website.

Outcomes

The consumer representatives from the TGA ACM and the TGA Advisory Committee on Medical Devices (ACMD) were officially ratified as members of the CCC.

Members welcomed the news that the Department of Health had established a dedicated “Unit” to allow the development of structured projects of engagement with consumer and patient groups. The *HTA Consumer Evidence and Engagement Unit* will be led by Dr Sally Wortley and will support the work of the HTA CCC as well as develop additional opportunities for consumer and patient impact and involvement across the HTA process.

Members discussed issues around the declaration of interests for consumer engagement and agreed to establish a register of interests for those who are members of the CCC.

The recent community forums hosted by the Patient Voice Initiative, with presentations provided by various members of the CCC were also discussed. Members agreed that this was a valuable collaboration and future opportunities to work together would be welcomed.

Members provided updates on various projects including the CCC mentoring project, the HTA website and the pilot PASC/MSAC consultation survey. These discussions helped inform the priorities for the HTA CCC 2019/2020 work plan.

Activities discussed for inclusion in the 2019/2020 work plan included:

- Development of an orientation/induction manual for Australian HTA consumer representatives
- HTA training and education workshops for patient groups
- Update of content and materials for publication on the HTA CCC webpages
- Evaluation of the pilot PASC/MSAC consultation survey, with a view to building a consistent survey for consumers across the HTA processes.

Next meeting

The next meeting is to be held in Canberra in June 2019 and will include a half-day workshop prior to the CCC meeting where a broader group of HTA consumer representatives from relevant Department of Health areas will be invited to attend.